Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...

As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children,” published in the November 2024 ...

Most positive tests for RSV so far this season in Canada have been among the youngest, federal data suggests. And while ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

Covid-19 hospitalizations, which typically rise throughout December and peak sometime in January, remain low for now.

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal ...